Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Flow cytometry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB2851-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human IFN-gamma Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human IFN-gamma in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse IFN-gamma , recombinant rat IFN-gamma , or recombinant porcine IFN-gamma is observed. Neutralizes the bioactivity of recombinant human IFN-gamma and will not neutralize the activity of rat or mouse IFN-gamma .
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
AAP20098.1
- Isotype
- IgG
- Antibody clone number
- 25723
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Interleukin-16-producing NK cells and T-cells in the blood of tobacco smokers with and without COPD.
Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers -- IL-12, IL-18 and IL-23.
Andersson A, Malmhäll C, Houltz B, Tengvall S, Sjöstrand M, Qvarfordt I, Lindén A, Bossios A
International journal of chronic obstructive pulmonary disease 2016;11:2245-2258
International journal of chronic obstructive pulmonary disease 2016;11:2245-2258
Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers -- IL-12, IL-18 and IL-23.
Piskin G, Tursen U, Sylva-Steenland RM, Bos JD, Teunissen MB
Experimental dermatology 2004 Dec;13(12):764-72
Experimental dermatology 2004 Dec;13(12):764-72
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of IFN- gamma in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) treated with 50 ng/mL PMA, 1 ug/mL Ionomycin, and 3 uM Monensin overnight were stained with either (A) Mouse Anti-Human IFN- gamma Monoclonal Antibody (Catalog # MAB2851) or (B) Mouse IgG2B Isotype Control (Catalog # MAB0041) followed by anti-Mouse IgG PE-conjugated secondary antibody (Catalog # F0102B) and Mouse Anti-Human CD3 epsilon APC-conjugated Monoclonal Antibody (Catalog # FAB100A). To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012). View our protocol for Staining Intracellular Molecules.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- IFN-gamma Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN-gamma Antibody. Recombinant Human IFN-gamma (Catalog # 285-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IFN-gamma (5 ng/mL) is neutralized (green line) by increasing concen-trations of Mouse Anti-Human IFN-gamma Monoclonal Antibody (Catalog # MAB2851). The ND50 is typically 0.2-0.6 µg/mL.